Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E7050 food-effect and single-dose pharmacokinetic study in healthy volunteers
NL-OMON34518Active, not recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of Golvatinib in Nonhematologic neoplasms (5 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Food effect on E7050 bioavailability, Single-dose pharmacokinetics of E7050 at higher doses and 1 more. Started Nov 2010; status: active, not recruiting.
02
Drugs
Golvatinib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON34518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34518.